On Demand:
New Drug Update 2025

April 24-26 2026, Key West Florida


”Fantastic presentation! So much great information. Wayne is brilliant!”

”Dr. Weart is amazing! I learned so much!

”Dr Weart is a phenomenal expert. Highly enjoyed this conference.”

”Thoroughly enjoyed Wayne! What a gift that he’s still enjoys sharing his vast knowledge with all of us.”

”Excellent review of important disease states, therapies, pharmacology, and pertinent studies that relate to those disease states.”

”Dr. Weart gave an excellent presentation. His overview was right on point, and I can’t wait to attend another one of his presentations.

About This Course

  • Recorded live in Key West On April 24-26 2026

  • Provides 10 Hours of ACPE Home Study credit.

  • Valid through April 26, 2029

  • Price $200

Learning Objectives

  1. Identify recent FDA drug communications, including but not limited to, labeling changes, warnings, new indications, new dosage forms and MedWatch alerts.

  2. Discuss the new drugs with respect to their pharmacology, pharmacokinetics, approved and unapproved indications.

  3. Describe their adverse effects and drug interaction that may affect patient compliance.

  4. Compare efficacy, dosage and cost to existing agent

  5. Discuss the patient oriented outcomes or evidence that may or may not exist for each of the new medications and when they may or may not be appropriate to recommend for selected patients.

  6. Compare pharmacotherapy outcomes vs cost/benefit between newly approved agents and existing or lower cost agents.

An older man with glasses wearing a blue plaid shirt, speaking and gesturing with his hand in an indoor setting.

Speaker

Dr. C. Wayne Weart | Pharm.D., BCPS, FASHP

Professor Emeritus of Family Medicine, Department of Family Medicine, Medical University of South Carolina, Professor Emeritus of Clinical Pharmacy & Outcome Sciences, South Carolina College of Pharmacy, MUSC Campus, Charleston, SC.

Learn More

Accreditation Information - ACPE On Demand

PHARMACISTS:

  • University Learning Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. These programs are accredited for all pharmacists. On-demand courses provide HOME STUDY credit only.

  • University Learning Systems is approved by CE Broker, Tracking #50-11357 and reports to the Florida Board of Pharmacy.

  • CONSULTANT PHARMACISTS: Some consultant pharmacist boards accept University Learning Systems courses for recertification either as is or with board approval. Please contact your board regarding course approval and ULS with any questions.

  • CANADIAN PHARMACISTS:Canadian Council on Continuing Education in Pharmacy (CCCEP)accepts courses accredited by the Accreditation Council for Pharmacy Education (ACPE).  This credit is applicable to health professionals who may require pharmacology credit.

NURSE PRACTITIONERS

  • American Nurses Credentialing Center (ANCC) : This course fulfills the pharmacotherapeutics/ pharmacology requirements for American Nurses Credentialing Center (ANCC) Continuing Education Hours  or certification renewal as well as other Nurse Practitioner credentialing organizations that accept ACPE credit. The same hours submitted to renew certification may be submitted to a State Board of Nursing for re-licensure.

  • American Association of Nurse Practitioners (AANP)   This program offers Category 2 credit only. AANP only accepts on demand courses approved for  AMA PRA Category 1 Credit™. 

NURSES

  • University Learning Systems is approved by theCalifornia Board of Registered Nursing, Provider Number CEP 11409, and CE Broker Tracking #50-11357:

  • CE Broker is approved by these Boards of Nursing: Arkansas, Florida, District of Columbia, Georgia, Kentucky, New Mexico, North Dakota, South Carolina, West Virginia.The same hours submitted to renew NP certification may be submitted to a State Board of Nursing for re-licensure.

PHYSICIANS/ PHYSICIAN ASSISTANTS:

OTHER HEALTH PROFESSIONALS: Please contact your respective board regarding approval.